Unplanned Readmissions of Children With Epilepsy in the United States

Sudha Kilaru Kessler1, Leah J Blank2, Jennifer Glusman3

  • 1Department of Neurology, Perelman School of Medicine, Philadelphia, Pennsylvania; Division of Pediatric Neurology, Department of Neurology, Perelman School of Medicine, Philadelphia, Pennsylvania; Pediatric Neurology Health Services Research Group, Department of Neurology, Perelman School of Medicine, Philadelphia, Pennsylvania.

Pediatric Neurology
|April 18, 2020
PubMed

Insights

Pediatric epilepsy readmissions occur in 10.4% of cases, with neurodevelopmental issues being key risk factors. Interventions should focus on these clinical comorbidities for better outcomes in children with epilepsy.

Area of Science:

  • Pediatric Neurology
  • Healthcare Quality Improvement
  • Epidemiology

Background:

  • Unplanned readmissions after pediatric epilepsy discharge in the U.S. remain understudied.
  • Epilepsy is a frequent cause of childhood hospitalization.

Purpose of the Study:

  • To determine the burden and characteristics of unplanned readmissions following pediatric epilepsy-related hospital discharge.
  • To identify risk factors associated with these readmissions.

Main Methods:

  • Retrospective cohort study using the 2013-2014 Nationwide Readmissions Database.
  • Analysis of children aged 1-17 years discharged after nonelective epilepsy hospitalization.
  • Descriptive statistics and logistic regression to assess readmission risk factors.

Main Results:

  • 10.4% of pediatric epilepsy admissions resulted in readmission within 30 days.
  • Epilepsy was the most common readmission diagnosis (24.9%).
  • Neurodevelopmental diagnoses (cerebral palsy, intellectual disability, developmental delay), longer hospital stays, gastrostomy, and tracheostomy were associated with increased readmission risk. Medicare insurance was linked to a 34.4% readmission rate.

Conclusions:

  • A benchmark pediatric epilepsy readmission rate of 10.4% can inform quality improvement initiatives.
  • Clinical factors, particularly neurodevelopmental comorbidities, are stronger predictors of readmission than demographic characteristics.
  • Targeting interventions towards children with neurodevelopmental comorbidities may effectively reduce pediatric epilepsy readmissions.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
528
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
133